Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment
Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment
复制标题
肝X受体激动剂T0901317逆转A549人肺癌细胞对EGFR-TKI治疗的耐药性
DOI：
10.1002/2211-5463.12147
复制
发表时间：
2017-01-01
期刊：
影响因子：
2.6
通讯作者：
Wu, Jianzhong
中科院分区：
文献类型：
--
作者：
Cao, Haixia;Yu, Shaorong;Wu, Jianzhong
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR-TKI- treatment. We found that T0901317 could make natural EGFR-TKI-resistant A549 human lung cancer cells sensitive to EGFR-TKI treatment and that this was dependent on LXR beta expression. However, T0901317 does not have a similar effect on another natural EGFR-TKI-resistant cell line H1650.
